Skip to main content

Advertisement

SpringerLink
Log in

Psychiatric disorders of the combination of levetiracetam either with lacosamide or perampanel: a retrospective cohort study

  • Research Article
  • Published:
International Journal of Clinical Pharmacy Aims and scope Submit manuscript

Abstract

Background The number of patients with epilepsy receiving perampanel or lacosamide as an add-on treatment following levetiracetam treatment has increased. Although levetiracetam causes psychiatric disorders, it is unclear whether they occur with the combined use of these antiepileptic drugs. Objective To determine the frequency of psychiatric disorders in patients received lacosamide or perampanel in combination with levetiracetam. Setting A single-center retrospective cohort study. Method Patients who received levetiracetam + lacosamide or levetiracetam + perampanel were selected. Medical records from the start of combination therapy contained characteristics of patients and the incidence of psychiatric disorders. Main outcome measure The frequency of psychiatric disorders, the time to onset, dose reduction or discontinuation following psychiatric disorders, and the clinical course following disorder onset. Results Forty-four patients used levetiracetam + lacosamide and 50 used levetiracetam + perampanel. The incidence of psychiatric disorders was significantly lower (p < 0.001) with levetiracetam + lacosamide (6.8%) than with levetiracetam + perampanel (44%). The incidence of affect lability was significantly higher with levetiracetam + perampanel than with levetiracetam + lacosamide (p = 0.018). The time to the onset of psychiatric disorders was within 1 month of dose initiation or increase in one case (33.3%) with levetiracetam + lacosamide and 16 cases (72.7%) with levetiracetam + perampanel. There was no significant difference in clinical characteristics and antiepileptic drug dosages owing to the presence or absence of psychiatric disorders. Conclusion As the frequency of psychiatric disorders was higher with levetiracetam + perampanel therapy, levetiracetam + lacosamide may be preferable. These disorders tended to develop within 1 month of therapy and were not dose-dependent. Antiepileptic drugs should be cautiously prescribed to avoid psychiatric disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Gilliam F. Optimizing health outcomes in active epilepsy. Neurology. 2002;58:S9–20.

    Article  Google Scholar 

  2. Baker GA, Jacoby A, Buck D, Stalgis C, Monnet D. Quality of life of people with epilepsy: a European study. Epilepsia. 1997;38:353–62.

    Article  CAS  Google Scholar 

  3. Perucca P, Carter J, Vahle V, Gilliam FG. Adverse antiepileptic drug effects: toward a clinically and neurobiologically relevant taxonomy. Neurology. 2009;72:1223–9.

    Article  CAS  Google Scholar 

  4. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342:314–9.

    Article  CAS  Google Scholar 

  5. Chen Z, Brodie MJ, Liew D, Kwan P. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study. JAMA Neurol. 2018;75:279–86.

    Article  Google Scholar 

  6. Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA. 2004;101:9861–6.

    Article  CAS  Google Scholar 

  7. French J, Arrigo C. Rapid onset of action of levetiracetam in refractory epilepsy patients. Epilepsia. 2005;46:324–6.

    Article  CAS  Google Scholar 

  8. Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet. 2004;43:707–24.

    Article  CAS  Google Scholar 

  9. Japanese Society of Neurology. Tenkan Shinryo Guideline 2018: Clinical Practice Guideline for Epilepsy 2018. Tokyo: Igakushoin; 2018 ISBN: 9784260035491.

    Google Scholar 

  10. Ceolin L, Bortolotto ZA, Bannister N, Collingridge GL, Lodge D, Volianskis A. A novel anti-epileptic agent, perampanel, selectively inhibits AMPA receptor-mediated synaptic transmission in the hippocampus. Neurochem Int. 2012;61:517–22.

    Article  CAS  Google Scholar 

  11. Beyreuther BK, Freitag J, Heers C, Krebsfänger N, Scharfenecker U, Stöhr T. Lacosamide: a review of preclinical properties. CNS Drug Rev. 2007;13:21–42.

    Article  CAS  Google Scholar 

  12. Chen B, Choi H, Hirsch LJ, Katz A, Legge A, Buchsbaum R, et al. Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy. Epilepsy Behav. 2017;76:24–31.

    Article  Google Scholar 

  13. Chen Z, Lusicic A, O’Brien TJ, Velakoulis D, Adams SJ, Kwan P. Psychotic disorders induced by antiepileptic drugs in people with epilepsy. Brain. 2016;139:2668–78.

    Article  Google Scholar 

  14. Hansen CC, Ljung H, Brodtkorb E, Reimers A. Mechanisms underlying aggressive behavior induced by antiepileptic drugs: focus on topiramate, levetiracetam, and perampanel. Behav Neurol. 2018;2018:2064027.

    Article  Google Scholar 

  15. Ettinger AB, LoPresti A, Yang H, Williams B, Zhou S, Fain R, et al. Psychiatric and behavioral adverse events in randomized clinical studies of the noncompetitive AMPA receptor antagonist perampanel. Epilepsia. 2015;56:1252–63.

    Article  CAS  Google Scholar 

  16. Hasegawa N, Fukuda M. The effect of lacosamide on psychiatric comorbidities in patients with epilepsy. Epilepsy Behav Rep. 2020;14:100402.

    Article  Google Scholar 

  17. Chung S, Williams B, Dobrinsky C, Patten A, Yang H, Laurenza A. Perampanel with concomitant levetiracetam and topiramate: post hoc analysis of adverse events related to hostility and aggression. Epilepsy Behav. 2017;75:79–85.

    Article  Google Scholar 

  18. Mula M, Trimble MR, Yuen A, Liu RSN, Sander JWAS. Psychiatric adverse events during levetiracetam therapy. Neurology. 2003;61:704–6.

    Article  CAS  Google Scholar 

  19. Perucca P, Jacoby A, Marson AG, Baker GA, Lane S, Benn EKT, et al. Adverse antiepileptic drug effects in new-onset seizures: a case-control study. Neurology. 2011;76:273–9.

    Article  CAS  Google Scholar 

  20. Martins HH, Alonso NB, Vidal-Dourado M, Carbonel TD, de Araújo Filho GM, Caboclo LO, et al. Are adverse effects of antiepileptic drugs different in symptomatic partial and idiopathic generalized epilepsies? The Portuguese-Brazilian validation of the Liverpool Adverse Events Profile. Epilepsy Behav. 2011;22:511–7.

    Article  CAS  Google Scholar 

  21. Josephson CB, Engbers JDT, Jette N, Patten SB, Singh S, Sajobi TT, et al. Prediction tools for psychiatric adverse effects after levetiracetam prescription. JAMA Neurol. 2019;76:440–6.

    Article  Google Scholar 

  22. Pinkhasov A, Lam T, Hayes D, Friedman M, Singh D, Cohen H. Lacosamide induced psychosis: case report, review of differential diagnosis and relevant pharmacokinetics. Clin Neuropharmacol. 2015;38:198–200.

    Article  Google Scholar 

  23. Chatzistefanidis D, Karvouni E, Kyritsis AP, Markoula S. First case of lacosamide-induced psychosis. Clin Neuropharmacol. 2013;36:27–8.

    Article  Google Scholar 

  24. Rosenfeld W, Conry J, Lagae L, Rozentals G, Yang H, Fain R, et al. Efficacy and safety of perampanel in adolescent patients with drug-resistant partial seizures in three double-blind, placebo-controlled, phase III randomized clinical studies and a combined extension study. Eur J Paediatr Neurol. 2015;19:435–45.

    Article  Google Scholar 

  25. Lagae L, Villanueva V, Meador KJ, Bagul M, Laurenza A, Kumar D, et al. Adjunctive perampanel in adolescents with inadequately controlled partial-onset seizures: a randomized study evaluating behavior, efficacy, and safety. Epilepsia. 2016;57:1120–9.

    Article  CAS  Google Scholar 

  26. Krauss GL, Perucca E, Ben-Menachem E, Kwan P, Shih JJ, Clément J-F, et al. Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: results from phase III extension study 307. Epilepsia. 2014;55:1058–68.

    Article  CAS  Google Scholar 

  27. Stephen LJ, Wishart A, Brodie MJ. Psychiatric side effects and antiepileptic drugs: observations from prospective audits. Epilepsy Behav. 2017;71:73–8.

    Article  Google Scholar 

  28. Carunchio I, Pieri M, Ciotti MT, Albo F, Zona C. Modulation of AMPA receptors in cultured cortical neurons induced by the antiepileptic drug levetiracetam. Epilepsia. 2007;48:654–62.

    Article  CAS  Google Scholar 

  29. Wood MD, Gillard M. Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein. Epilepsia. 2017;58:255–62.

    Article  CAS  Google Scholar 

  30. Yates SL, Fakhoury T, Liang W, Eckhardt K, Borghs S, D’Souza J. An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam. Epilepsy Behav. 2015;52:165–8.

    Article  Google Scholar 

  31. Brodie MJ, Besag F, Ettinger AB, Mula M, Gobbi G, Comai S, et al. Epilepsy, antiepileptic drugs, and aggression: an evidence-based review. Pharmacol Rev. 2016;68:563–602.

    Article  Google Scholar 

Download references

Funding

No funding was received to assist with the preparation of this manuscript.

Author information

Authors and Affiliations

  1. Department of Pharmacy, Tokyo Medical University Hachioji Medical Center, 1163 Tatemachi, Hachioji City, Tokyo, Japan

    Satoru Matsunuma & Koichi Yoshimoto

  2. Department of Neurosurgery, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan

    Shigeki Sunaga & Hiroyuki Jimbo

  3. Department of Emergency and Critical Care Medicine, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan

    Akira Hoshiai & Takao Arai

Authors
  1. Satoru Matsunuma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shigeki Sunaga
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Akira Hoshiai
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Takao Arai
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hiroyuki Jimbo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Koichi Yoshimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Satoru Matsunuma.

Ethics declarations

Conflicts of interest

The authors have no relevant financial or non-financial interests to disclose.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Matsunuma, S., Sunaga, S., Hoshiai, A. et al. Psychiatric disorders of the combination of levetiracetam either with lacosamide or perampanel: a retrospective cohort study. Int J Clin Pharm 43, 1516–1522 (2021). https://doi.org/10.1007/s11096-021-01274-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11096-021-01274-7

Keywords

Search

Navigation